TP53 and cancer: In addition, SMYD2 is reported to methylate the K370 site of p53 repressing its antitumor effect (Huang et al., 2006), whereas SMYD2 induces RB1 methylation at lysine 810 in some cancers that promotes cell cycle progression of these malignant cells (Cho et al., 2012).